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Prolonged Inhaled Allergen Exposure Can Induce
Persistent Tolerance
Chris L. Van Hove, Tania Maes, Guy F. Joos, and Kurt G. Tournoy
Ghent University, Faculty of Medicine and Ghent University Hospital, Department of Respiratory Diseases, Ghent, Belgium
Murine asthma models suggest that failure of immune tolerance
rather than a defective T helper cell type 1 (Th1) immunity underlies
the immune biology of Th2-driven allergen-induced airway disease.
Intriguingly, prolonged exposures can result in a full waning of
inflammation. Themechanisms underlying this observation are not
understood. We hypothesized that the fading of inflammation is
the result of regulatory processes, characterized byaltereddendritic
cell (DC)–T cell interactions. First, we implemented amodel inwhich
mice developed Th2-driven airway disease. When we subjected
these mice to prolonged antigen ovalbumin (OVA) exposures (8 wk),
all inflammation disappeared. Re-immunization and re-challenge
showed an inability to mount Th2-skewed immune responses, with
absence of airway eosinophils, IgE, and Th2 cytokines. Besides spe-
cific immune tolerance, bystander protection was observed. A de-
crease in CD4CD25Foxp3 T-regulatory cells, PD-1, and IL-10
expression was discerned as compared with acute inflammation.
In addition, suppression of ICOS and CD28 was found, along with
inhibited DC maturation. This process of disease inhibition surpris-
ingly had a long-lasting memory and was not caused by endotoxin
signaling through TLR-4. In summary, our results indicate that the
disappearanceof Th2-driven airwaydisease uponpersistent antigen
exposure is associated with the induction of immune tolerance.
The tolerant state is antigen-dependent, and extends to bystander
antigens. Moreover, this tolerance is characterized by an altered
DC–T cell communication and is long-lasting. Our data further sug-
gest that the mechanism of the disease inhibition after allergic
airway inflammation differs from the anti-inflammatory mecha-
nisms observed during acute eosinophilic airway inflammation.
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Both experimental and clinical data provide abundant evidence
for the central role of activated T helper type 2 (Th2) cells in
the allergen-induced airway inﬂammation observed in asthma
(1). A number of murine asthma models mimic the features
of this disease and allow the study of underlying cellular and
molecular mechanisms (2). The Th2-driven airway changes in
these models are mainly evoked by exposure of the airways to
the archetypic antigen ovalbumin (OVA) for 2–7 d after systemic
sensitization.
Based on these animal models but also on growing clinical
data, a change in paradigm has recently been proposed in which,
instead of a Th1/Th-2 imbalance, failing tolerance mechanisms
are thought to be decisive in the pathogenesis of Th2-driven
allergic airway disease (3). This view is plausible because toler-
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CLINICAL RELEVANCE
It becomes clear now that a failure of immune tolerance
explains allergic airway inﬂammation. Our data demon-
strate that despite allergen exposure, immune tolerance can
be restored. In addition, our research characterizes the
immune mechanisms involved.
ance is the normal functional outcome after allergen exposure
in healthy nonatopic individuals or nonsensitized naı¨ve animals.
In addition, it has been shown that mice, made tolerant by means
of inhalation or feeding of OVA, are protected against subse-
quent allergen-induced airway disease, mainly due to the effects
of CD4CD25Foxp3 regulatory T cells (4) or other regulatory
T cell subsets (5, 6).
While the available animal models of asthma focus on acute
airway inﬂammatory changes, modeling chronic asthma remains
problematic. Prolonging allergen exposure in sensitized animals
has been reported to be associated with a disappearance of the
inﬂammatory changes (7–10). Several research groups have been
searching for ways to avoid this waning of inﬂammation to mimic
more closely the chronic nature of human asthma (10–13). How-
ever, we appreciated this fading away of inﬂammation as impor-
tant, since it essentially models the control of unwanted airway
inﬂammation. Up to now, it is not known whether the observed
disappearance of inﬂammation represents a passive phenomenon
or an active, immune-mediated process. In addition, the immuno-
logic characteristics of this observation remain unknown.
To address these questions experimentally, we here imple-
ment a model in which sensitized mice are exposed to inhaled
allergen, establishing Th2-driven airway disease. By prolonging
the allergen exposure, we conﬁrm that the allergic airway in-
ﬂammation disappears completely. We provide the proof of con-
cept that these observations are the consequence of an active,
immune-mediated tolerance. We ﬁnd that, concurrent with eo-
sinophilic airway disease, counter-regulatory mechanisms be-
come activated. Our data suggest that different mechanisms are
involved in the inhibition of inﬂammation upon sustained anti-
genic challenge. These suppressive mechanisms are antigen de-
pendent and extend to bystander allergens, while they induce
a long-term protective memory. We investigate the roles of
IL-10, CD4CD25Foxp3 regulatory T cells, DC–T cell inter-
actions, and TLR-4 signaling in this process of disease inhibition,
and indicate the differential importance of the inducible costimu-
lator (ICOS), CD28, and programmed death (PD)-1 receptor.
MATERIALS AND METHODS
Animals
C57BL/6 mice (males, 6–8 wk old) were purchased from Harlan (Zeist,
the Netherlands). IL-10 knockout (KO) mice (C57BL/6-IL10tm1/Cgn,
males, 6–8 wk), the corresponding C57/BL6 wild-type (WT) controls,
Toll-like receptor (TLR)-4 KO mice (C57BL/10ScNJ, 6–8 wk), and
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the C57BL/10 WT controls (6–8 wk) were purchased from Jackson
Laboratories (Bar Harbor, ME). All experimental procedures were
approved by the local ethical committee for animal experiments
(Faculty of Medicine and Health Sciences, Ghent University, Ghent,
Belgium).
Allergen Exposure Protocols
Short- and long-term OVA exposure protocols—Protocol 1. To character-
ize the effects of short- versus long-term allergen exposure in sensitized
mice, groups of 8 C57BL/6 mice were sensitized with 10 g OVA
(GradeV; Sigma, St. Louis,MO) adsorbed to 1mgAl(OH)3 intraperito-
neally on Days 0 and 7. From Day 14 onward, the mice were exposed
to aerosolized OVA (1% wt/vol, Grade III; Sigma) or PBS 30 min/d,
three times per week for 2 and 8 wk, respectively (Figure 1, Protocols
1A and 1B). For analysis, the mice were killed 24 h after the last
exposure.
Speciﬁc and bystander immune tolerance: re-immunization and re-
challenge protocols—Protocol 2. To analyze the effects of long-term
antigen exposure on the immune system, OVA-sensitized C57BL/6
mice (n  8/group) previously subjected to the long-term OVA chal-
lenge protocol were re-sensitized with OVA/alum and re-challenged
with OVA aerosols (OVA/OVA-exposed group). Groups of OVA-
Figure 1. Allergen exposure protocols. Protocol 1. (A ) Ex-
posure of OVA sensitized C57BL/6 mice to PBS or OVA
aerosols for 2 wk. (B ) Prolonged PBS or OVA aerosol expo-
sure in OVA-sensitized mice (8 wk). Protocol 2. (A ) Re-
sensitization with OVA/alum and re-challenge with OVA
or PBS aerosols (1 wk) after long-term OVA or PBS aerosol
exposure in OVA-sensitized mice. (B ) Re-sensitization with
the bystander allergen HEL (HEL/alum) and challenge
(1 wk) with this secondary allergen or PBS after prolonged
OVAor PBS aerosol exposure inOVA-sensitizedmice. Proto-
col 3. Re-sensitizationwithOVA/alumand re-challengewith
OVA or PBS aerosols (1 wk) after prolonged OVA or PBS
aerosol exposure followed by an 8-wk resting period. Proto-
col 4. Re-sensitization (HEL/alum) and challenge with the
bystander allergen HEL or PBS after only 2 wk of OVA or
PBS aerosol exposure. Protocol 5. Re-sensitization with
OVA/alum and re-challenge with OVA or PBS aerosols
(1 wk) after only 2 wk of OVA or PBS aerosol exposure
followed by an 8-wk resting period.
sensitized but PBS-challenged mice were also re-immunized and re-
challenged with either OVA (PBS/OVA–exposed group; positive con-
trol) or PBS (PBS/PBS–exposed group; negative control) (Figure 1,
Protocol 2A). IL-10 KO mice and TLR-4 KO mice were also subjected
to this protocol. For analysis, the mice were sacriﬁced 24 h after the
last exposure.
In Protocol 2B, OVA sensitized C57BL/6 mice (n  8–11/group)
subjected to the long-term OVA challenge protocol were re-sensitized
and re-challenged with the bystander allergen hen egg lysozyme (HEL;
Sigma) (10 g HEL/alum intyraperitoneally) (OVA/HEL-exposed
group). Positive and negative control groups were included (PBS/HEL-
and PBS/PBS-exposed groups, respectively) (Figure 1, Protocol 2B).
For analysis, the mice were killed 24 h after the last exposure.
Memory response protocol—Protocol 3. To analyze whether the im-
mune inhibition upon of long-term antigen exposure has memory
characteristics, OVA-sensitized mice (n  8/group) were subjected to
the long-term protocol (8 wk OVA exposure), followed by an 8-wk
resting period (5–10% of the lifetime expectancy). Next, mice were re-
immunized and re-challenged with OVA (Figure 1, Protocol 3) (OVA/
OVA group). Positive and negative control groups were included (PBS/
OVA and PBS/PBS). For analysis, the mice were killed 24 h after the
last exposure.
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Bystander response short protocol—Protocol 4. To analyze whether
short-term antigen exposure inherently activates immune inhibitory
mechanisms, we shortened the period of OVA exposure from 8 wk
down to 2 wk before re-sensitizing and re-challenging (n  8/group)
with HEL (Figure 1, Protocol 3) (OVA/HEL-exposed group). Positive
and negative control groups were included (PBS/HEL and PBS/PBS
groups). For analysis, the mice were killed 24 h after the last exposure.
Speciﬁc immune tolerance: importance of long-term exposure—
Protocol 5. In Protocol 5 we examined whether the long-term antigen
exposure was necessary to obtain full and persistent disease inhibition.
Therefore, four groups of OVA-sensitized (Day 0) C57BL/6 mice
(n  8/group) were challenged for only 2 wk to either OVA or PBS
(Days 14–28), followed by 8 wk without exposure. After re-immunization
with OVA (Day 84), the mice were exposed for 1 wk to either OVA
or PBS (Days 91–98). Positive and negative control groups were PBS/
OVA and PBS/PBS exposed, respectively, while the OVA/OVA-
exposed group was the test group (Figure 1, Protocol 5). The OVA/
PBS group represented an additional test group and was included to
examine the natural declining of inﬂammation. For analysis, the mice
were killed 24 h after the last exposure.
Bronchoalveolar Lavage: Cellular Analysis
Twenty-four hours after the last aerosol exposure, mice were killed with
an intraperitoneal pentobarbital injection (60 mg/kg; Sanoﬁ, Libourne,
France). Bronchoalveolar lavage (BAL) ﬂuid was taken as described
(14). Brieﬂy, three lavages with 0.3 ml HBSS followed by three lavages
with 1 ml HBSS were performed via a tracheal cannula. The BAL ﬂuid
of the ﬁrst three fractions was centrifuged and the supernatant was
used for cytokine detection. The cell pellet was then added to the rest
of the lavage ﬂuid for cell counts on cytospins (May-Gru¨nwald/Giemsa).
Tissue Processing and Lung Single-Cell Suspension for Flow
Cytometric Analysis
After BAL, lung digest was performed as described previously (15),
followed by cell counting and labeling for ﬂow cytometry. Cell counting
was performed with a Z2 Beckman-Coulter particle counter (Beckman-
Coulter, Ghent, Belgium). Flow cytometric analysis of dendritic cells
(DC) and T-lymphocytes on lung single-cell suspensions and on BAL
ﬂuid was conducted as deﬁned previously (15–17). Monoclonal antibod-
ies used to identify mouse DC (sub)populations were biotinylated anti-
CD11c (N418 hybridoma; gift fromM.Moser, Brussels Free University,
Brussels, Belgium) and phycoerythrin (PE)-conjugated anti-IAb and
anti-CD86 (Becton Dickinson BD, Erembodegem, Belgium). Anti-rat
IgG2a-PE was used for isotype control. DCs were identiﬁed based on
their low autoﬂuorescence, and high CD11c and IAb expression proﬁles
as described (15). Markers used for mouse T cell subpopulations stain-
ing were anti–CD3-APC, –CD4-FITC, –CD4-PercP, –CD25-PE,
–CD28-PE, –CTLA-4-PE (BD) and anti–ICOS-PE, –PD-1-PE and
–Foxp3-PE (e-Bioscience, San Diego, CA). Isotype controls were PE-
conjugated anti-rat IgG1, -rat IgG2a,, -golden Syrian hamster IgG,
and -rat IgG2b, and FITC-conjugated anti-rat IgM,. Biotinylated anti-
bodies were revealed using streptavidin-APC. Before analysis, cells
were incubated with 7-amino-actinomycin (7-AAD or Viaprobe; BD)
for dead cell exclusion. Foxp3 (FJK-16 s) is a transcription factor and
hallmark of CD4CD25 regulatory T cells and requires intracellular
staining achieved by cytoﬁx/cytoperm. Flow cytometry data acquisition
was performed on a dual laser FACSCalibur ﬂow cytometer running
CELLQuest software (BD, Mountain View, CA). FlowJo software
(www.Treestar.com) was used for data analysis.
Histology
After ﬁxation of the left lung with 4% paraformaldehyde, slices from
all left lobes were embedded in parafﬁn for histology. Sections of 2 m
were stained with Congo Red. The slides were coded and the peribron-
chial (and perivascular) inﬂammation was graded in a blinded fashion
using a reproducible scoring system described elsewhere (18). A value
from 0 to 3 was adjudged to each tissue section scored. A value of 0 was
given when no inﬂammation was detectable, a value of 1 for occasional
cufﬁng with inﬂammatory cells, a value of 2 when most bronchi were
surrounded by a thin layer of inﬂammatory cells (1 to 5), and a value
of 3 when most bronchi were surrounded by a thick layer of inﬂamma-
tory cells ( 5). As 5–7 tissue sections per mouse were scored, inﬂam-
mation scores could be expressed as a mean value per animal and could
be compared between groups.
Lymph Node Cell Cultures
Lung draining lymph nodes were harvested into tissue culture medium
(TCM) containing tubes and digested to obtain a single-cell suspension.
Cells were cultured in TCM in a ﬂat-bottom, 96-well plate (BD) with
100 g OVA, at a density of 8  105 cells per well. After 5 d of culture,
supernatants were harvested and frozen for cytokine measurements.
IgE and Cytokines
Total, OVA- and HEL-speciﬁc IgE in serum and IL-4, IL-5, IL-13,
IFN- , IL-10, thymus and activation regulated chemokine (TARC) in
the BAL ﬂuid and supernatant of cultured lymph nodes were measured
using ELISA kits (R&D Systems, Abingdon, UK).
RT-PCR
Total lung RNA was extracted using the RNeasy Midi kit (Qiagen,
Hilden, Germany), with an additional DNase step. Reverse transcrip-
tion was performed at 48	C for 30 min followed by 12 min incubation
at 95	C for denaturation of RNA–DNA heteroduplexes, and a DNA
ampliﬁcation with 50 cycles of 95	C for 15 s and 60	C for 1 min. RT-
PCR was performed starting from 10 ng of total RNA, using an ABI
PRISM 7700 Sequence Detection System (Applied Biosystems, Foster
City, CA). IL-13, IFN-, and foxp-3 mRNA relative to hypoxanthine
guanine phophoribosyl transferase (hprt)mRNA, was analyzed with the
Assays-on-Demand Gene Expression Products (Applied Biosystems).
Statistical Analysis
Data were analyzed with the statistical packet SPSS 14.0 (SPSS Inc.,
Chicago, IL). Values are expressed as mean 
 SEM. Groups were
compared using the Kruskal-Wallis test for screening signiﬁcant differ-
ences between the groups. When P  0.05, Mann-Whitney U-test with
Bonferroni’s conservative corrections were applied to compare the indi-
vidual groups.
RESULTS
Persistent Antigen Exposure Inhibits Th2-Driven
Airway Inflammation
C57BL/6 mice, sensitized and challenged for 2 wk with OVA
aerosol (Figure 1, Protocol 1A), had a signiﬁcant increase in the
total amount of leukocytes in BAL ﬂuid as compared with the
control mice exposed to PBS aerosols (Figure 2). This was pri-
marily due to the inﬂux of eosinophils, although increases in the
number of macrophages and lymphocytes were also present.
Histopathology of the lungs showed cufﬁng of the bronchi with
mononuclear cells and eosinophils. This airway inﬂammation
was parallelled with increases in total serum (not shown) and
antigen-speciﬁc IgE, while in BAL ﬂuid and in supernatant of
cultured lymph node cells the Th2 cytokine IL-13 and chemokine
TARC were both increased (Figure 2). Next, we challenged
these mice for 6 (data not shown) or 8 wk with OVA (Figure 1,
Protocol 1B). At these time points, we found that in BAL ﬂuid,
eosinophils were absent while the total number of leukocytes
had returned to baseline.AlthoughOVA-IgE remained elevated
as compared with PBS-challenged mice, histopathology of the
lungs showed the complete absence of peribronchial eosinophilic
inﬂammation. OVA-IgE did not, however, differ between the
mice challenged with OVA for 2 or 8 wk (P  N.S.). The fading
of inﬂammation was also paralleled with a return to baseline of
both IL-13 and TARC, measured in the BAL ﬂuid (Figure 2),
as well as on supernatant of cultured lymph node cells (data not
shown). IFN- in these compartments did not differ between
the groups (data not shown).
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Figure 2. (A ) BAL fluid cellular differentials (cytospins),
serum OVA-IgE (in U/ml), histology scores, and BAL
fluid cytokines in Protocols 1A and 1B. (B ) Photomicro-
graphs of Congo Red–stained sections of the airways
ofOVA-sensitized and -challengedmice (magnification:
100) in Protocol 1A (OVA 2 wk) and Protocol 1B
(OVA 8 wk). Analogous results for IL-13 and TARC were
obtained from the supernatant of cultured lymph node
cells. n  8/group *P  0.05, **P  0.005, OVA versus
PBS.
Persistent Antigen Exposure Induces Antigen-Specific and
Bystander Immune Tolerance
To prove that the waning of Th2 airway inﬂammation upon
persistent antigen exposure was the result of an immune-
mediated tolerance, we had to show resistance of the mice to
developing new acquired immune responses upon re-immuniza-
tion and re-challenge. Therefore, we re-sensitized and shortly
re-challenged the mice that had been exposed to OVA aerosols
for 8 wk with OVA (OVA/OVA-exposed group) (Figure 1,
Protocol 2A). Sensitized mice exposed to 8 wk of PBS were,
after the second immunization, re-challenged with either OVA
(positive control group; PBS/OVA) or PBS (negative control
group; PBS/PBS).
We found that mice subjected to 8 wk of OVA aerosol expo-
sure were completely resistant to develop Th2 skewing. This is
underscored by the absence of eosinophils in BAL ﬂuid, while
the pulmonary tissue showed no inﬂammation at all. Speciﬁc
and total (not shown) serum IgE were suppressed, as were
IL-13 and TARC in BAL ﬂuid (Figure 3A). IL-10 levels in BAL
ﬂuid were below the detection limit ( 5 pg/ml) in the mice
exposed to 8 w of OVA aerosols. This was similar to negative
control mice, but contrasted with mice suffering acute inﬂamma-
tion (12.7 
 1.7 pg/ml). Although IL-4 and IL-5 were below the
detection limit in BAL ﬂuid, we could detect IL-4, IL-5, IL-10,
and IL-13 in the supernatant of cultured (OVA-stimulated)
lymph node cells. These cytokines were signiﬁcantly suppressed
in the OVA/OVA-exposed mice as compared with the mice
suffering acute allergen-induced airway disease (PBS/OVA group;
data not shown).
Next, we measured whether the inhibition of immune re-
sponses was also present in the face of nonrelated antigens.
When we changed the antigen of the second immunization and
re-challenge, and used HEL instead of OVA, we found that the
induced immune tolerance had bystander characteristics. The
mice, immunized and challenged with OVA for 8 wk, were not
able to develop Th2-skewing for HEL (OVA/HEL group). No
BAL eosinophils, increases in HEL-speciﬁc IgE (inOptical Den-
sities,O.D.), airway inﬂammation, orBAL IL-13 or TARCcould
be discerned (Figure 3B). This contrasts with mice initially ex-
posed to 8 wk of PBS aerosols. These developed pronounced
Th2 responses when immunized and challenged with HEL (i.e.,
positive control group PBS/HEL). Cytokine patterns similar to
those found in the BAL ﬂuid were detected on cultured lymph
node cells (not shown). Analysis of lung tissue by RT-PCR
also resulted in a similar pattern for IL-13 mRNA, while IFN-
mRNA did not differ between the groups (data not shown).
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Figure 3. BAL fluid cellular differen-
tials (cytospins), serum OVA-IgE (U/
ml), and HEL-IgE (Optical Densities,
O.D.), histology scores and cytokines
in BAL fluid (IL-13 and TARC) in Proto-
col 2A (A ) and Protocol 2B (B ). n 
8–11/group; *P  0.05, **P  0.005
versus OVA/OVA or OVA/HEL.
Alterations in DC–T Cell Communication Are Associated
with the Inhibition of Disease after Eosinophilic
Airway Inflammation
As a next step, we investigated the role of the
CD4CD25Foxp3 T-regulatory cells and co-stimulatory
molecules on DC and T cells (Figure 1, Protocol 2). We chose
to analyze the expression of ICOS and PD-1 on T cells and
the presence of Foxp3 in CD4CD25 T cells because these
markers have been implicated in the induction of tolerance. In
addition, we evaluated theDC–T cell communication by examin-
ing the presence of CD80/CD86 on DC and of CD28 on T cells.
The CD4 lung T cells from mice suffering acute Th2 airway
disease (PBS/OVA exposed) expressed more CD28 and ICOS
as compared with the negative control mice (PBS/PBS exposed;
Figure 4A). This was paralleled by an increase in the number of
DC in both BAL ﬂuid and lung tissue (Figure 4B). In addition,
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Figure 4. Flow cytometric analysis of the expression
of co-stimulatory molecules on lung CD4 T cells
in Protocol 2A, as percentage of double-positive cells
within the T cell population (A ). Flow cytometric
analysis of BAL fluid and lungDC number andmatu-
ration status (percentage of CD86 and MHCII) of
pulmonary DC in Protocol 2B (B ). n  8/group;
*P  0.05, **P  0.005 versus OVA/OVA or OVA/
HEL.
a more mature DC phenotype with an increased expression of
MHC class II (MHCII) and CD80/86 in both tissue compart-
ments was found (Figure 4B). Intriguingly, during acute inﬂam-
mation, signiﬁcant increases were found in the percentage
of CD4 T cells expressing PD-1 as well as in the mRNA ex-
pression of Foxp3 (data not shown), and in the number of
CD4CD25Foxp3 cells as compared with the negative control
mice (Figure 4A).
In contrast, the tolerant mice chronically exposed to OVA
had a marked suppression of CD28 and ICOS expression on the
CD4 T cells as compared with the mice suffering acute disease
(PBS/OVA exposed), although the expression of these co-
stimulatory molecules was still higher as compared with the
negative control mice (PBS/PBS exposed; Figure 4A). The num-
ber of BALﬂuid and lungDCwas reduced in these tolerantmice,
while their maturation status (CD80/86-MHCII expression) was
signiﬁcantly inhibited when compared with the mice suffering
acute disease (Figure 4B). Numbers and phenotype of DC in
the tolerant mice did even not signiﬁcantly differ from negative
control animals. Remarkably, in the tolerant mice, there was
less Foxp3 mRNA (not shown), and a signiﬁcantly reduced per-
centage of CD4CD25Foxp3 cells and PD-1CD4 T cells
as compared with themice suffering acute airway disease (Figure
4A). While the percentage of these cells was still higher than in
negative control mice, their absolute numbers in did not signiﬁ-
cantly differ from negative control mice (not shown).
The Protection upon Persistent Exposure Has a Long-Lasting
Immune Memory
Next, we veriﬁed whether the observed resistance to develop
Th2 skewing was only a temporary or long-lasting phenomenon.
Therefore, in the mice that had been exposed to 8 wk of OVA,
a time-out of another 8 wk was introduced before Th2 renewal
was attempted (Figure 1, Protocol 3). Thus, we exposed mice
to long-term OVA aerosols, and subsequently rested them for
a period of 8 wk. We then re-immunized and re-challenged
themwith OVA (OVA/OVA). Our results showed that the mice
presented with a complete protection against Th2 skewing: no
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eosinophils or increases in other inﬂammatory cells could be
found in the BAL ﬂuid or around the airways (Figure 5). In line
with these results, Th2 cytokines in BAL (Figure 5A) and in
supernatant of cultured lymph node cells (data not shown) corre-
spond with the baseline levels found in mice that had never been
challenged (PBS/PBS) and were signiﬁcantly lower than in mice
suffering acute Th2 skewing (PBS/OVA). The production of
serum OVA-speciﬁc and total IgE (not shown) was inhibited in
the OVA/OVA-exposed mice (Figure 5A). The latter also had
signiﬁcantly lower percentages of lung CD4CD25Foxp3,
CD4 PD-1 T cells, and CD4CD28 and CD4ICOS cells
Figure 5. BAL fluid cellular dif-
ferentials (cytospins), serum
OVA-IgE (U/ml), histology
scores, and BAL fluid cytokines
in Protocol 3 (memory re-
sponse protocol) (A ). Analo-
gous results for IL-13 and TARC
were obtained from the super-
natant of cultured lymph node
cells (B ). Flow cytometric anal-
ysis of the expression of co-
stimulatory molecules on lung
CD4 T cells in Protocol 4, as
percentage of double-positive
cells within the T cell popula-
tion. n  8/group; *P  0.05,
**P  0.005 versus OVA/OVA.
(Figure 5B) when compared with the positive control mice (PBS/
OVA-exposed).
During Eosinophilic Inflammation, the Counter-Regulatory
Mechanisms Are Functionally Characterized by
Immune Inhibition
After the observation that concurrent with acute eosinophilic
inﬂammation, increases in CD4CD25Foxp3 T cells (Proto-
cols 2 and 3) were found, we investigated whether parameters
of disease inhibition could be demonstrated at a functional level
in the period just after the induction of acute airway disease.
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Therefore, a new experiment was performed in which mice, with
acute eosinophilic airway disease were stimulated to develop a
new immune response in the face of a nonrelated antigen,
in casu HEL (Figure 1, Protocol 4). We hypothesized that mice
suffering recently induced Th2 skewingwould already have func-
tional characteristics of disease inhibition. Indeed, sensitized
mice exposed to OVA for only 2 wk and re-immunized and
exposed to HEL (OVA/HEL) displayed partial inhibition of
Th2 responses as compared with mice that suffered full-blown
inﬂammation (PBS/HEL). The development of eosinophilia in
BAL ﬂuid, HEL-speciﬁc serum IgE, pulmonary inﬂammation,
and Th2 cytokine production were all signiﬁcantly inhibited
(Figure 6). TARC was also inhibited in these mice, but was still
higher as compared with the negative control group (PBS/PBS).
The Counter-Regulatory Mechanisms Activated during Acute
Allergic Airway Inflammation Are Not Sufficient to Induce
Full and Persistent Disease Inhibition
Faced with the facts that in sensitized mice, long-term antigen
exposure can induce tolerance mechanisms resulting in a full
(Protocol 2) and persistent (Protocol 3) disease control on the
one hand, and that sensitized mice suffering acute Th2-mediated
inﬂammation have discernible and functionally active anti-
inﬂammatory mechanisms (Protocol 4) on the other hand, it
remained to be established if the long-term exposure to antigen
was necessary to obtain a full and persistent inhibition of disease.
This hypothesis was tested in Protocol 5 (Figure 1, Protocol 5).
In this protocol, we included an additional group (OVA/PBS-
exposed) to evaluate the natural declining of inﬂammation.
We found that exposing sensitized mice to OVA for only 2 wk,
followed by a resting period (6–8 wk) and then followed by a
re-sensitization and re-challenge episode, resulted in a signiﬁcant
reappearance of eosinophilic airway disease in the OVA/OVA-




and BAL fluid cytokines in
Protocol 4 (bystander re-
sponse short protocol).
n  8/group; *P  0.05,
**P  0.005 versus OVA/
HEL.
exposed test group. This was evidenced by increased BAL ﬂuid
cell numbers and the reappearance of BAL ﬂuid eosinophils
(Figure 7A), as well as by the re-appearance of eosinophilic
pulmonary inﬂammation. Although we were not able to detect
increases in IL-13 and IgE, the chemokine TARC was increased
in the OVA/OVA group as compared with the negative control
group (Figure 7A). Nevertheless, the magnitude of the eosino-
philic airway inﬂammation (absolute numbers of BAL ﬂuid
eosinophils, the pulmonary inﬂammation; TARC and IL-13 con-
centration) was still signiﬁcantly lower in the OVA/OVA group
as compared with the positive control group (PBS/OVA-
exposed). The additional group (“OVA/PBS”) investigating the
natural declining of inﬂammation shows that inﬂammation
has already waned at the moment of re-sensitization and re-
challenge. The patterns of expression of CD28 and to a lesser
extent the expression patterns of ICOS and PD-1 on lung
T cells, as well as the percentage of CD4CD25Foxp3 regula-
tory T cells in the lung, are consistentwith the patterns previously
observed during acute inﬂammation, as was the case for the
number of DC (not shown). In summary, the data of Protocol
5 show that long-term OVA aerosol exposure is needed for the
development of full and persistent mucosal tolerance.
The inhibition of Disease Is Not Mediated through
TLR-4 Signaling
In a ﬁnal set of experiments, we tested whether LPS signaling
through the TLR-4 receptor was involved, since the TLR-4 re-
ceptor represents a major pathway for endotoxin to exert its
immunologic effects. First, we measured the LPS contamination
in the OVA used for nebulization (grade III; Sigma) by limulus
amoebocyte lysate (LAL) assay. The OVA used contained 5.82
pg LPS/g OVA.
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Figure 7. A.BAL fluid cellular differentials
(cytospins), serum OVA-IgE (Units/ml),
histology scores and BAL fluid cytokines
in Protocol 5 (A ). Analogous results for
IL-13 and TARC were obtained from the
supernatant of cultured lymph node cells.
(B ) Flow cytometric analysis of the expres-
sion of co-stimulatory molecules on lung
CD4 T cells in Protocol 5, as percentage
of double-positive cells within the T cell
population (B ). n  8/group; *P  0.05,
**P  0.005 versus OVA/OVA.
Next,we usedC57/BL10TLR-4KOmice and the correspond-
ing C57/BL10 WT mice in Protocol 2A shown in Figure 1. Our
data indicated that in both WT and in TLR-4 KO mice, long-
term exposure to OVA induced a state of disease inhibition
after the eosinophilic airway inﬂammation. This was again evi-
dent from the absence of eosinophils in BAL ﬂuid, of airway
inﬂammation, serum IgE and the Th-2 cytokine IL-13, and the
chemokine TARC (Figure 8). The inhibition of disease was
comparable between the two strains and was complete, as these
parameters corresponded with their baseline levels (PBS/PBS).
DISCUSSION
The data presented here support the hypothesis that ﬁrm and
long-lasting control of allergen-induced airway inﬂammation
by inducing immune tolerance is feasible. In sensitized mice
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Figure 8. BAL fluid cellular differentials (cytospins), serum total IgE (g/ml), histology scores and BAL fluid cytokines in TLR-4 KO mice subjected
to Protocol 2A. Analogous results for IL-13 and TARC were obtained from the supernatant of cultured lymph node cells. n  7/group; **P  0.005
versus OVA/OVA.
exposed to OVA aerosols for 8 wk (“long-term” or “chronic”),
marked alterations in the DC-T cell phenotype and co-stimulatory
molecule expression were observed. A reduced expression of
ICOS andCD28 on theCD4T cells and of CD80/86 andMHCII
on the DC was found compared with active inﬂammation. In
addition, we showed that the mechanisms involved in long-term
disease control were not characterized by increases in
CD4CD25Foxp3T-regulatory cells, IL-10 secretion or PD-1.
On the contrary, these markers were even down-regulated. This
differs from the counter-regulatory mechanisms activated early
on during an acute inﬂammatory process or upon preventive
inhalational or oral tolerance induction (4, 5).
Although discontinuous administration of antigens such as
OVAhas been reported to result in a persistentmoderate airway
inﬂammation (7), and although other studies using house dust
mite (11) orAspergillus fumigatus (19) extracts have documented
the establishment of chronic eosinophilic airway inﬂammation,
a number of reports, as well as our current data, have indicated
the possibility to obtain a full control of airway inﬂammation
upon continued antigen exposure (7–9). The disappearance of
the inﬂammation in our model was not only evident in the BAL
ﬂuid, but also in the lung tissue and is underscored by the waning
of the Th2 cytokines and chemokines such as IL-13 and TARC.
The mechanisms underlying this observation are unknown,
although of potential relevance to control airway inﬂammation
in patients with asthma.
First, we hypothesized that the resolution of inﬂammation
was the consequence of an active, immune-mediatedmechanism.
This was tested by re-immunizing and by re-challenging the mice
in which airway inﬂammation had disappeared, after 8 wk of
antigen exposure. Indeed, a ﬁrm protection against Th2 skewing
with an inability to mount eosinophilic disease, IgE and Th2
cytokines and chemokines was found. By deﬁnition, these obser-
vations show the induction of immune tolerance, the latter being
the absence of an acquired immune response in face of an antigen
for which the immune system has the capability to respond (20).
These mice thus behaved as being in a condition of disease
inhibition after eosinophilic airway inﬂammation.
Second, we tested whether several mediators involved in tol-
erance induction upon feeding or inhaling a protein antigen
before sensitization were involved (4, 6, 21). Prominent roles of
CD4CD25Foxp3 T-regulatory cells (4, 21), tolerogenic DC
(6), the immunomodulatory cytokine IL-10 (22), and even ICOS
(5) have been indicated. The role of ICOS in this context is dual,
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since ICOS–ICOSL coupling plays a role in both the induction
of Th2 diseases (23) and in T-regulatory cell–mediated tolerance
(5, 24, 25). The inhibitory molecule PD-1 has also been implicated
in peripheral tolerance induction (26, 27). In mice made tolerant
by long-term OVA aerosols, we found, after re-immunization and
re-challenge, a signiﬁcant reduction in both BAL ﬂuid and pul-
monary DC compared with mice suffering acute eosinophilic
airway disease. A decrease in “myeloid” DC, as identiﬁed here
(15), has been causally linked to the waning of inﬂammation
after repeated allergen exposure (28), possibly by altering the
ratio with the tolerogenic “plasmacytoid” DC (29). The percent-
age of lung and BAL ﬂuid DC expressing CD80/86 was also
signiﬁcantly reduced. First, this altered DC maturation status
suggests that the inhibition of disease cannot simply be explained
by anergic T cells, since anergy is a state of nonresponsiveness
of the T cells despite optimal conditions of stimulation. Second,
the co-stimulatory molecules CD80/86 have been implicated in
ICOS expression (30). Indeed, we found on the CD4 T cells a
signiﬁcant reduction in the expression of both ICOS and CD28,
the latter also implicated in ICOS expression (30). Taken to-
gether, these data indicate that these mice have acquired resis-
tance to DC maturation and subsequent T cell activation, which
explains why no adaptive immune response could be mounted.
IL-10 secretion in the BAL ﬂuid and supernatant of cultured
lymph node cells of the chronically challenged mice was de-
creased upon re-sensitization and re-challenge. Although there
is one study that reported IL-10–independent inhalational toler-
ance (31), the data we obtained from an experiment using
IL-10 KOmice did not allow a clear interpretation (Protocol 2B;
data not shown). Therefore, the possible role of IL-10 remains to
be established in this model of tolerance induction. Intriguingly,
we detected a decrease in the percentage and absolute numbers
of CD4CD25foxp3 T-regulatory cells in the lungs of the
chronically challenged mice compared with the mice suffering
acute eosinophilic airway disease. The absolute number of this
T cell subset did not differ from negative control. These data
suggest that that the number of these cells is not important in
the inhibition of disease after long-term OVA challenge. How-
ever, with our data, we cannot formally exclude an enhanced
regulatory activity of these cells to explain the observed anti-
inﬂammatory effect.
One could propose that the observations of full disease inhibi-
tion and the reduction of the co-stimulatory molecule expression
on DC and CD4 T cells upon chronic antigen exposure are the
consequence of a temporary exhaustion of the immune system.
By scheduling an 8-wk resting period after chronic exposure and
before re-immunization and re-challenge, we could show that
the status of disease inhibition after the eosinophilic airway
inﬂammation had memory characteristics. This indicates that the
immune system had acquired a very efﬁcient protective memory,
persistently inhibiting new adaptive immune responses for a
period covering 5–10%of the average life expectancy of amouse.
Even after an 8-wk resting period without antigen challenge,
the number of CD4CD25Foxp3 remained low, as did the
expression of CD28 and ICOS.
These observations in tolerant mice were thus in contrast
with mice suffering acute eosinophilic inﬂammation, in which
an up-regulation of CD4CD25Foxp3 T cells along with an
increased expression of IL-10 and PD-1 was seen, indicating that
these anti-inﬂammatory mechanisms became activated concur-
rent with the eosinophilic inﬂammation. The apparent duality
in the presence of both pro-inﬂammatory and anti-inﬂammatory
mechanisms led us to test functionally whether mice suffering
from eosinophilic airway inﬂammation had simultaneous charac-
teristics of immune inhibition. We found that a secondary immu-
nization and challenge with another antigen immediately after
short-term exposure (2 wk) to the primary antigen OVA, did
not result in overt airway disease as compared with control mice,
which previously did not suffer from eosinophilic airway disease
(Protocol 4). An inhibition of bystander IgE and of airway eosin-
ophilia by  90% shows that anti-inﬂammatory mechanisms
were already engaged, despite the recently induced eosinophilic
airway disease, and illustrates that tolerogenic mechanisms were
active even during eosinophilic airway disease. These anti-
inﬂammatory mechanisms, active during eosinophilic inﬂamma-
tion, were nevertheless not sufﬁcient to induce a full and persis-
tent inhibition of disease upon subsequent re-immunization and
re-challenge (Protocols 3 and 5). In other words, only chronic
exposure to antigen (8wk) was able to induce a full and persistent
waning of inﬂammation.
It was also possible that the inhibition to develop inﬂamma-
tory responses was codetermined by exogenous factors such as
ubiquitously present, contaminating endotoxin. This hypothesis
made sense from a theoretical point of view, since there is epide-
miologic evidence implicating endotoxin as a protective factor
against asthma (32). In a mouse model, it has been shown that
high doses of endotoxin (10g/d) can inhibit eosinophilic airway
inﬂammation, although this was accompanied by a shift toward
a Th1 response, as identiﬁed by IFN- and neutrophilic pneumo-
nitis (33). Moreover, in a mouse model of prolonged OVA chal-
lenge, endotoxin has been reported to down-regulate allergic
airway inﬂammation through TLR-4 signaling (34). Others nev-
ertheless reported inhalational tolerance that was not mediated
by endotoxin (35). Our data clearly show that signaling through
the TLR-4 receptor did not critically mediate the disease inhibi-
tion after eosinophilic airway inﬂammation, since we observed
very similar protective effects in both TLR-4 KO and WT mice.
In summary, our results indicate that the resolution of Th2-
driven airway disease upon persistent antigen exposure is ex-
plained by the induction of immune tolerance. This immune
tolerance is antigen dependent and extends to bystander aller-
gens. It is characterized by a ﬁrm and long-lasting inhibition of
DC maturation and of the co-stimulatory molecules CD28 and
ICOS on T cells. Moreover, no up-regulation of IL-10, PD-1,
or CD4CD25Foxp3 T-regulatory cells was discovered. LPS
signaling through the TLR-4 receptor was not involved in the
induction of inhalational tolerance. Our data suggest that the
mechanisms of the disease inhibition after eosinophilic airway
inﬂammationmay differ from the anti-inﬂammatorymechanisms
that become activated during acute eosinophilic airway disease.
Further elucidation of these mechanisms could reveal important
players implicated in controlling allergic airway inﬂammation.
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